FTO and myeloid leukemia: More particularly, FTO inhibitors, meclofenamic acid (MA), or its ethyl ester form (MA2) have been recently identified as specific FTO inhibitors that have shown antitumor activity on myeloid leukemia (AML) and GBM, prostate, and uterine cervical cancers [12,53,54,55,56].